| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.01 | 1 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.0097 | 1 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.0084 | 1 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.0046 | 1 |